In November, Kyowa Hakko Bio Co., Ltd. and Kyowa Hakko USA, Inc., a subsidiary of Kirin Holdings Company, Limited celebrated of the opening of its expanded citicoline manufacturing facilities at the Kyowa Hakko Bio Yamaguchi Production Center, situated in Hofu City, Yamaguchi Prefecture, Japan. The occasion marks a significant milestone in the company’s growth journey. Kyowa Hakko Bio President and CEO, Yuki Kanzaki, underscored the pivotal role of Cognizin in the company’s future success.

Cognizin has a history of global use in enhancing cognitive function in health foods. With the global population aging and the rapid growth of the e-sports market, which is expected to expand at an annual rate of 7 percent between 2018 and 2023, the demand for citicoline has surged, especially in the United States, where it is sought after for use in supplements and functional food and beverages, according to the company.

Kyowa Hakko Bio’s expansion of citicoline manufacturing capacity not only meets this growing demand but also establishes a resilient global supply network catering to pharmaceutical and health food manufacturers, the company stated. Moreover, the Kirin Group said that it is excited about integrating citicoline into its upcoming product development initiatives, further solidifying its commitment to health and well-being.

For more information, visit https://kyowa-usa.com.